Press release 2011-01-14

Agreement with Paracelsus Medical University at Salzburg Universitätsklinik, Austria to clinically integrate the C-RAD GEMini imaging detector

C-RAD AB with its four fully owned subsidiaries are all active in the field of radiation therapy. C-RAD AB and the Paracelsus Medical University at Universitätsklinik für Radiotherapie und Radio- Onkologie in Salzburg, Austria have signed an agreement to clinically integrate the GEMini ED detector with an Elekta linac system.

Universitätsklinik für Radiotherapie und Radio- Onkologie in Salzburg is one of the leading clinics in advanced radiation therapy in Austria. The clinic has four linac systems from Elekta installed. The Paracelsus Medical University has a long experience in flat panel imaging and is continuously working on a software platform for radiation therapy called open-radART with related imaging modules. The Clinic and the University have long term relationships with Elekta and Siemens.

The C-RAD project has been planned in three different phases. The first phase is integration and pre-clinical test phase carried on an Elekta linac with the GEMini detector on a trolley. On condition that objectives have been achieved the second phase will start. In this phase the GEMini ED panel will be integrated with the Elekta linac. After approval the detector will be acquired by the clinic. In the last phase the work on specifications in a clinical setting will continue. This phase might also include other activities of mutual interest of the parties.

Results will continuously be presented to linac industry.

Erik Hedlund, CEO, C-RAD AB:

"The agreement with the radiation therapy clinic and the medical university in Salzburg is very important in order to show clinical implementation and data to main vendors in the field coming from a GEMini system on site. Together with the experienced group in Salzburg we are convinced we will be able to present superior performance with the GEMini ED detector."

Heinz Deutschmann, administrative head of radART institute at Paracelsus Medical University, chief physicist:

“Promising detector properties, such as increased quantum efficiency, higher imaging frame rates and the panel’s potential for dual energy (kV/MV) imaging make the device very interesting for our IGRT (image guided radiotherapy) solutions: Low MU port verification,

2D/3D registration tasks and real time adaptive tracking solutions will gain from C-RAD technology. We are expecting a prolonged lifespan due to radiation hardness of GEMini's active area, which will improve clinical reliability of portal imaging and serve our patients. Having contributed to progress in radiotherapy by development of improved flat panel imaging with amorphous silicon devices in the past, we are honored to be the first clinic worldwide to co-operate with C-RAD on clinical integration and validation of new GEMini detector technology."

For further information:

Erik Hedlund, CEO C-RAD AB, Telefon 018 - 66 69 31, E-post erik.hedlund@c-rad.se

---

About C-RAD AB

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 19 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel^{TM,} started in 2007. Cooperation agreements have been signed with the Swedish company Elekta and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.